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Abstract
Background: Given the polymicrobial nature of pulmonary infections in patients with cystic fibrosis (CF), it is essential to
enhance our knowledge on the composition of the microbial community to improve patient management. In this study, we
developed a pyrosequencing approach to extensively explore the diversity and dynamics of fungal and prokaryotic
populations in CF lower airways.
Methodology and Principal Findings: Fungi and bacteria diversity in eight sputum samples collected from four adult CF
patients was investigated using conventional microbiological culturing and high-throughput pyrosequencing approach
targeting the ITS2 locus and the 16S rDNA gene. The unveiled microbial community structure was compared to the clinical
profile of the CF patients. Pyrosequencing confirmed recently reported bacterial diversity and observed complex fungal
communities, in which more than 60% of the species or genera were not detected by cultures. Strikingly, the diversity and
species richness of fungal and bacterial communities was significantly lower in patients with decreased lung function and
poor clinical status. Values of Chao1 richness estimator were statistically correlated with values of the Shwachman-Kulczycki
score, body mass index, forced vital capacity, and forced expiratory volume in 1 s (p=0.046, 0.047, 0.004, and 0.001,
respectively for fungal Chao1 indices, and p=0.010, 0.047, 0.002, and 0.0003, respectively for bacterial Chao1 values).
Phylogenetic analysis showed high molecular diversities at the sub-species level for the main fungal and bacterial taxa
identified in the present study. Anaerobes were isolated with Pseudomonas aeruginosa, which was more likely to be
observed in association with Candida albicans than with Aspergillus fumigatus.
Conclusions: In light of the recent concept of CF lung microbiota, we viewed the microbial community as a unique
pathogenic entity. We thus interpreted our results to highlight the potential interactions between microorganisms and the
role of fungi in the context of improving survival in CF.
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Introduction
The human respiratory tract represents the major portal of
entry for numerous microorganisms, primarily those occurring as
airborne particles such as viral and bacterial entities, or fungal
spores. Microorganism characteristics coupled with the local host
immune response will determine whether they will be cleared or
adhere and colonize the airways leading to acute or chronic
pulmonary disease.
In cystic fibrosis (CF), mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene result in
defective mucociliary clearance and, as a consequence, lead to the
production of thick and sticky bronchial mucus, which facilitates
the entrapment of airborne viruses, bacteria and fungal spores and
provides a suitable environment for the growth of these
microorganisms. In addition to bacteria, which are well known
to cause recurrent exacerbations of CF-associated pulmonary
disease and often determine the vital prognosis of patients [1],
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36313many fungi also colonize the respiratory tract of CF patients [2–5],
although their involvement in respiratory infections remains
controversial and largely unsolved [6,7]. As an alternative to
conventional methods (direct examination and microbiological
cultures), new molecular techniques such as pyrosequencing, have
been developed to offer a more complete view of the microbiota.
In human samples, these molecular methods can distinguish
microorganisms difficult to identify and/or those that are
refractory to culture (such as Pneumocystis jirovecii, Scedosporium
apiospermum, atypical mycobacteria, etc.), as well as new or as yet
unknown pathogens [8–10]. The metagenomic approach has been
recently used for the identification of human bacterial populations
in the gut as well as in the mouth saliva and skin of patients [11–
15]. In addition, metagenomic studies have been successfully used
for providing an overview of community composition with semi-
quantitative information [13,14,16–19]. Some studies have been
published on the human respiratory tract, but only few have
specifically focused on microbial diversity in CF [16–18,20–25].
In the present study, we applied a molecular approach by
pyrosequencing variable regions of bacterial 16S rDNA and fungal
ITS2 genes in sputum samples from CF patients. Our aims were to
explore the fungal and bacterial assemblages in CF patients to
achieve a better understanding of species/taxon diversity and
population dynamics of the microbiota, and their relevance for the
clinical course of pulmonary disease in CF.
Results
Samples and patients
We prospectively collected eight sputum samples from four CF
adult patients (median age of 29.5 years; Q1, 24.5; Q3, 34) who
were all part of a long-term follow-up program at Lille’s Adult CF
center. Two temporal sputum samples were collected from each
clinically stable patient with a sampling interval of 1 year; for
Patient 4 the sampling interval was only three months (Tables 1
and 2). Three out of the four patients were homozygous or
heterozygous for the DF508 mutation.
Results of the Shwachman-Kulczycki score (S-K score), body
mass index (BMI), forced vital capacity (% of predicted FVC), and
forced expiratory volume in 1 s (% of predicted FEV1) expressed
as medians (Q1, Q3) were 55.0 (50.0; 90.0), 20.4 (17.1; 22.85),
75.0 (48.0; 111.5), and 53.0 (41.0; 90.0), respectively. None of the
CF patients had pancreatic alterations. All patients had bacteria
present in their sputa, as determined by culturing, but none were
known to be chronically infected with Staphylococcus aureus or
Burkholderia cepacia complex. Using conventional methods, we
identified mucoid and non-mucoid Pseudomonas aeruginosa, meticil-
lin-sensitive Staphylococcus aureus, Haemophilus influenzae, and Alcalig-
enes xylosoxidans (Table 2). No oropharyngeal flora was detected,
and no mycobacteria were isolated. Two patients (Patients 1 and
4) were colonized by P. aeruginosa and treated with azithromycin, as
recommended for chronic P. aeruginosa infections. Both patients
had severe airway disease as assessed by the S-K score (S-K score
#50%), BMI (under 16 for Patient 4) and standard spirometry
(FEV1,50% of predicted FEV1) (Table 1). Patients 2, 3 and 4
were treated with inhaled corticosteroids, and Patient 4 received
systemic corticoids (Table 1). Only Patient 1 received long-term
itraconazole treatment (600 mg per day for 6 months) for allergic
bronchopulmonary aspergillosis (ABPA).
Regarding fungi, Candida albicans and Geotrichum sp., and two
filamentous species, Aspergillus fumigatus and Aspergillus flavus, were
isolated from sample cultures. Aspergillus nidulans, Aspergillus terreus,
S. apiospermum, Scedosporium prolificans,o rExophiala dermatitidis were
not isolated. In addition, P. jirovecii colonization was retrospectively
diagnosed in three out of four patients. Both sputum samples of
Patient 2, as well as one of Patient 1 (sample 2) and Patient 4
(sample 1) were nested PCR-positive for P. jirovecii (Table 2) [26].
Aspergillus DNA was detected using an ultrasensitive real-time PCR
assay [27] in five of the eight sputum samples (Table 2).
Overall richness and diversity of microbial community
evaluated from pyrosequences
We obtained a total of 326,277 sequences from samples 1 and 2
of Patients 1, 2, 3 and 4 using primers for the prokaryote 16S
rDNA gene, a result in agreement with recent published data [17]
(Figure 1A). Using the fungus-specific ITS2 primers, we obtained a
total of 133,317 sequences from these samples (Figure 1B). Once
primer, tag and key fragments were removed, 93% and 85% of the
sequences had lengths greater than 450–500 bp and 300–450 bp
for the 16S rDNA and ITS2 loci, respectively.
The pyrosequences that presented similarities with sequences
available in databases but that could not be classified to at least the
level of kingdom using BLASTN and MEGAN software were
designated as ‘‘not assigned’’ and excluded from subsequent diversity
analyses. For each sputum sample, these sequences represented less
than 5% of the 16S rDNA or ITS2 sequences included in analyses,
except for Patient 1-sample 2 and Patient 2-sample 2, which showed
9.7% and 8.4% of non-assigned 16S rDNA and ITS2 sequences, and
29.4% of non-assigned ITS2 sequences, respectively. Pyrosequences
without any similarity with sequences available in databases were
designated as ‘‘no hits’’, and may represent species not yet
represented in databases. Unsurprisingly, there were more ‘no hits’
for ITS2 pyrosequences than in 16S rDNA pryosequences (Tables 3
and 4, Figures S1, S2, S3, S4), due to the massive amount of data
available in the Silva SSU rDNA database compared to the
ITS2dbScreen database created expressly for the present analysis
(see Materials and Methods). Un-represented organisms in sequence
databases have already been described as a limitation in the ability to
placing reads in the phylogeny [28].
For all patients and samples except one (i.e. Patient 1-sample 1
for the ITS2 locus), the rarefaction curves for the number of
OTUs per pyrosequence reads reached a plateau, indicating that
almost all OTUs present in each sample were detected. The
apparent observed diversity was higher for the prokaryote 16S
rDNA locus (Figure 1A) in comparison to the fungus-specific ITS2
locus (Figure 1B).
Calculated to analyze microbial diversity, Chao1 richness
estimator values corroborated rarefaction curves, confirming high
bacterial diversity (Figure 2A). Bacterial diversity was higher in
samples from Patients 2 and 3 than in samples from Patients 1 and
4. Fungal diversity showed a similar pattern (Figure 2B).
Comparison of the culture and pyrosequencing results
Our results confirmed the new genera recently identified in CF
patients [8,16,17,20,23,24,29–31], with Gemella sp. being found in
sputum samples of 3 out of 4 patients (Table 3, Figures S1A–S4A).
The most represented genera identified in the present study were
Pseudomonas, Streptococcus, Haemophilus, and anaerobes, in agreement
with published data [1,16,17,20,23,24,30,31]. Bacteria belonging
to Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Haemophilus,
Veillonella, and Porphyromonas genera were isolated as recently
reported in either sputum or BAL samples from CF patients
(Table 3) [16,18,20,21,23,30].
High fungal diversity was also observed in samples, with more
than 60% of the fungal species or genera obtained in
pyrosequencing not identified by mycological cultures (Tables 1,
2 and 3, Figures S1B–S4B). Among the 24 species or genera of
micromycetes identified by pyrosequencing, only four were also
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identified additional species, especially within the genera Candida
and Aspergillus, which are microorganisms known to be involved in
pulmonary diseases or infectious diseases [3,4,32–45]. Geotrichum
sp., which represents an important pathogenic genus with
teleomorphs assigned to Dipodascus [35], was identified to the
family level using the pyrosequencing method (Table 4, Figure
S1B), due to the stringent parameters chosen to assign ITS2
sequences. Phylogenetically distinct from the A. fumigatus cluster,
non-fumigatus Aspergillus isolates were molecularly identified in
Patient 2-sample 1 (Figure S5), in agreement with RT-PCR results
(Table 2), which detects the mitochondrial DNA of A. fumigatus as
well as other species such as A. flavus [27]. Aspergillus lentulus, which
represents a species difficult to differentiate from A. fumigatus solely
based on phenotype criteria but has decreased susceptibility to
azoles [45–47], was isolated from Patient 3-sample 2 (Figure S3B).
The major expected advance from the high-throughput sequenc-
ing method was its ability to identify difficult-to-culture micro-
mycetes, such as P. jirovecii or Malassezia sp. Although nested-PCR
targeting P. jirovecii was positive in 4 sputum samples (Table 2),
high-throughput sequencing did not identify this fungus, probably
because there is only one copy of the ITS2 locus in the Pneumocystis
genome [48]. Malassezia restricta was identified in all patients
(Table 4, Figures S1B–S4B), and Malassezia globosa and Malassezia
sympodialis were molecularly identified in Patient 2 samples (Figure
S2B). These results are consistent with the lipophilic nature that
characterizes these yeasts and prevents their growth in standard
culture media because they require an exogenous source of fatty
acids [35]. Malassezia spp are frequently found in the skin of warm-
blooded vertebrates, and they are currently recognized as
emerging infectious pathogens [4,35]. Recently, Malassezia has
been identified in sputum samples from CF patients [25].
Since results from the conventional and high-throughput
sequencing techniques concurred, the pyrosequencing method
was used to identify dominant taxa, estimate their diversity, and
analyze their temporal distribution, based on data obtained from
both bacterial and fungal primers.
Fungal diversity and associated patterns of bacterial flora
The relative amounts of each species were estimated from the
number of assigned pyrosequences, and were represented by pie
charts whose diameters are proportional to the number of assigned
sequences (Figures S1, S2, S3, S4). According to recent
publications [19,22], the number of pyrosequences obtained
corresponds to the number of genome copies present in the
sputum sample. The median (Q1, Q3) number of microorganism
genera per sputum sample was 3.5 (3; 7.5) micromycetes and 6.5
(5; 13.5) bacteria; these results were comparable to those of
previous studies [1,8,9,29,31]. We observed bacterial diversity
similar to that recently reported in CF patients using molecular
methods [1,8,17,20,23,24,29–31], with anaerobic bacteria repre-
senting a large proportion of the detected species (ranging from
2% to 50% of total pyrosequences for Patient 1-sample 1 and
Patient 3-sample 2, respectively). For the kingdom Fungi, the
133,317 pyrosequences corresponded to 30 species or genera,
including 24 micromycetes and 6 basidiomycetous macroscopic
fungi. Among them, filamentous fungi belonging to the genera
Aspergillus (in particular Aspergillus fumigatus), and Penicillium have
already been described as pathogens in CF patients [2–5,35,45].
Candida albicans and species from the Candida parapsilosis complex
have been recently recognized as medically important organisms
colonizing CF patients [2,4,40,42,43]. Although their clinical
relevance is still matter of debate, long-term persistence of Candida
strains have been described in CF respiratory tracts
[4,40,42,43,49]. Clavispora is a yeast genus that includes Clavispora
lusitaniae (teleomorph of Candida lusitaniae); this ascomycete has
already been isolated from sputa [36,40].
A significant proportion of other species were either fungi
reported in asthma (Didymella exitialis, Penicillium camemberti), allergy
diseases (Aspergillus penicilloides and Eurotium halophilicum)
[32,33,37,39,50], or infectious diseases (Kluyveromyces lactis, Malas-
sezia sp., non-neoformans Cryptococci, Chalara sp.) [34–36,41]. The
other species or genera represented environmental taxa, either
described as wood-inhabiting fungi common in temperate regions
of the Northern Hemisphere, such as cereal pathogens associated
Table 2. Microbiological data from CF patients included in the study.
Sample Identification Conventional analysis of sputum
Bacteriological culture Mycological culture Molecular analysis
Patient- sample Bacteria DE
a Fungi Nested PCR
b rt-PCR
c
Patient 1-sample 1 Pseudomonas aeruginosa (mucoid texture)
Alkaligenes xylosoxidans
0 Candida albicans Geotrichum sp 22
Patient 1-sample 2 P. aeruginosa (mucoid texture) 0 C. albicans + 2
Patient 2-sample 1 ND
d 0 C. albicans ++
Patient 2-sample 2 Haemophilus influenzae 0 Aspergillus fumigatus C. albicans ++
Patient 3-sample 1 Staphylococcus aureus (sensitive to meticillin) 0 A. fumigatus Aspergillus flavus 2 +
Patient 3-sample 2 S. aureus (sensitive to meticillin) PH,H
e A. fumigatus C. albicans 2 +
Patient 4-sample 1 P. aeruginosa (mucoid texture) 0 C. albicans + 2
Patient 4-sample 2 P. aeruginosa (non-mucoid texture) P. aeruginosa
(mucoid texture)
H C. albicans A. fumigatus 2 +
aDE, direct examination;
bNested PCR was used to identify Pneumocystis jirovecii colonization [26];
crt-PCR, real-time polymerase chain reaction assay to detect Aspergillus fumigatus [27];
dND, not done;
ePH, Pseudo-hyphae and H, hyphae.
doi:10.1371/journal.pone.0036313.t002
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addition, macromycetes living on the wood of tree species
common in Europe including in northern France, were identified
in sputum samples from Patients 1, 2, and 4 (Figures S1B, S2B,
S4B), probably corresponding to the signature of the outdoor
environment that the patients are exposed to [54–56].
A growing number of studies has revealed that bacterial
[1,8,17,20,23,24,29,30,57,58] and fungal [9,25] community com-
positions vary greatly among patients. Diversity at sub-species
levels has also been described in CF, mainly for bacteria such as P.
aeruginosa [17,57,58], and to a lesser degree for fungi [9,25] or
viruses [18]. Therefore, the microbial community was currently
considered to be a unique pathogenic entity with potential
interactions between microorganisms [17,59–61]. From the
perspective of this microbiota concept, we phylogenetically
analyzed the diversity of the main fungi and bacteria identified
by pyrosequencing, considered the taxon composition of each
sample with potential interactions between fungi and bacteria, and
investigated its clinical significance.
Population dynamics of the microbial communities in CF
airways and clinical relevance
Although we observed lower diversity in CF airways than in
other communities such as human skin, gut, or water microbiomes
[12,14,19], reduced diversity and richness of fungal and bacterial
Figure 1. Rarefaction curves. These curves are representing the numbers of OTUs with respect to the number of pyrosequence reads obtained
from each patient at different sampling times and using the two set of primers targeting prokaryotic 16S rDNA (A) and fungal ITS2 (B) loci.
doi:10.1371/journal.pone.0036313.g001
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from the S-K score and BMI values, and decreased lung function,
as measured by FEV1 and FVC values, in CF (Figure 2). Chao1
values were statistically correlated with values of the S-K score,
BMI, FVC, and FEV1 (p=0.046, 0.047, 0.004, and 0.001,
respectively, for Chao1 indices of fungal species, and p=0.010,
0.047, 0.002, and 0.0003, respectively, for Chao1 values of
bacterial species). Moreover, fewer fungus species were detected in
sputum samples with lower FEV1 values; the correlation trended
toward significance (p=0.062). In parallel, a significant correlation
Table 3. Number of 16S-pyrosequencing reads assigned to each taxonomic group of Bacteria.
Sequences (reads)
a per patient and per sample
Identification Patient 1 Patient 2 Patient 3 Patient 4
Sample1 Sample2 Sample1 Sample2 Sample1 Sample2 Sample1 Sample2
ACTINOBACTERIA
Actinomycetales 0 7 17 10 0 0 0 0
Actinomyces 6 11 47 44 32 0 0 0
Rothia 0 0 458 158 15 0 0 0
Atopobium 0 0 9 0 0 0 0 0
BACTEROIDETES
Bacteroidales 0 0 10 7 0 0 0 0
Porphyromonas 0 0 145 0 0 29 0 0
Prevotellaceae 0 0 15 15 27 14 0 0
Prevotella 98 8 784 2098 620 11 10 0
FIRMICUTES 003 8 8 2 0 0 0 0
Bacilli 0 0 32 0 17 0 0 0
Bacillales 0 0 5 0 0 0 0 0
Gemella 0 0 113 22 79 0 10 0
Lactobacillales 0 0 12 16 9 0 0 0
Enterococcus 0 0 40 10 30 0 0 0
Streptococcus 5 7 255 931 446 5 6 0
Clostridia 0 0 0 0 0 0 0 0
Clostridiales 0 0 11 39 35 0 0 0
Mogibacterium 0 0 6 0 0 0 0 0
Eubacterium 0 0 0 0 11 0 0 0
Catonella 0 0 0 0 18 0 0 0
Veillonellaceae 0 0 0 8 0 0 0 0
Megasphaera 0 0 7 33 0 0 0 0
Veillonella 8 6 63 236 104 6 0 0
FUSOBACTERIA
Fusobacterium 0 0 46 19 6 5 0 0
Leptotrichia 0 0 0 5 5 0 0 0
PROTEOBACTERIA 47 41 30 19 6 51 50 67
Betaproteobacteria 6 7 0 0 0 0 0 0
Alcaligenaceae 6 0 0 0 0 0 0 0
Neisseriaceae 0 0 0 0 14 0 0 0
Neisseria 0 0 35 15 0 5 0 16
Campylobacter 0 0 6 7 118 0 0 0
Gammaproteobacteria 1349 4622 68 9 0 5370 1303 1666
Pasteurellaceae 0 0 255 83 0 11 0 0
Haemophilus 0 0 124 5476 0 5 5 0
Moraxella 0 0 74 0 0 0 0 0
Pseudomonas 5851 230 0 0 0 833 6744 8298
Stenotrophomonas 0 0 0 0 0 5 0 0
aOnce a read was assigned to the highest taxonomical level according to the criteria defined in material and method section, it was not added up in the next taxonomic
level.
doi:10.1371/journal.pone.0036313.t003
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Sequences (reads)
a per patient and per sample
Identification Patient 1 Patient 2 Patient 3 Patient 4
Sample1 Sample 2 Sample1 Sample2 Sample1 Sample2 Sample1 Sample2
DIKARYA 9 7 3 61 41 025 2 1 8
ASCOMYCOTA 0 1 43 12 61 85 0 51 2
Saccharomyceta 6 257 129 199 7 4 38 107
P e z i z o m y c o t i n a 001002 0 1
Leotiomyceta 1 1 1722 216 89 188 0 104
Dothideomycetes 0 1 10 7 0 0 0 0
C r y p t o c o c c u s 000000 0 1 4 5
Didymella 0 117 0 0 0 0 0 0
Phaeosphaeria 007000 0 0
Eurotiomycetes 0 0 18 0 0 0 0 0
E u r o t i o m y c e t i d a e 004037 0 0
Eurotiales 000135 0 1
Trichocomaceae 0 0 120 462 1108 2661 0 129
E u r o t i u m 001 3 000 0 0
Mitosporic Trichocomaceae 009562 0 4
Aspergillus 0 0 403 0 13 8 0 15
Penicillium 0 0 25 306 0 0 0 0
Neosartorya 0005 5 7 1 8 8 7 5 1 7 9 0 2 3 9
S o r d a r i o m y c e t a 002000 0 0
Helotiales 009000 0 0
Chalara 0 0 17 0 0 0 0 0
Sclerotiniaceae 0006 9 00 0 0
S o r d a r i o m y c e t e s 800700 0 0
Hypocreales 400000 0 0
Nectria 16 0 0 0 0 0 0 0
Xylariales 000010 0 0
Physalospora 000051 2 0 0
Saccharomycetes 001000 3 3 3 0 0
Saccharomycetales 9 60 92 60 198 0 808 116
Dipodascaceae 11 0 0 10 0 0 0 0
Clavispora 0 0 139 0 0 0 0 0
Candida 202 8688 5126 7167 6078 0 1173 6916
Saccharomycetaceae 12 0 4 0 0 0 398 0
Kluyveromyces 483 0 0 0 0 0 0 0
Saccharomyces 000000 8 0
Torulaspora 0 0 20 0 0 0 0 0
BASIDIOMYCOTA 101 0 4 2 9 00 2 7 4
Agaricomycotina 0 0 13 1 0 0 2 5
Agaricomycetes 0 0 477 16 0 0 58 20
Hyphodontia 000000 4 8 8 0
Coriolaceae 002000 0 0
Piptoporus 0 0 103 30 0 0 0 0
P h l e b i o p s i s 000000 0 4 2
Russulales 001000 0 0
Peniophora 0 0 204 0 0 0 0 0
Stereum 0 0 33 0 0 0 0 0
Agaricomycetidae 002000 0 0
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sample and values of S-K scores, BMI, FVC and FEV1 was
observed (p=0.0005, 0.03, 0.0003, 0.016 respectively) in agree-
ment with published data [23,58].
As previously observed [1,30], anaerobes were significantly
isolated in association with Pseudomonas, when comparing the
relative amount of reads in each sample (p=0.0003). Using a
phylogenetic method, most Pseudomonas pyrosequences proved to be
highly similar and clustered with sequences of P. aeruginosa strains
isolated from CF patients or endotracheal tube biofilms (Figure S6)
[62]. They also exhibited high infraspecific diversity, in agreement
with previous results [57,58]. The next most common bacterial
genus was Streptococcus, of which the Streptococcus milleri group (SMG)
has been isolated in CF [1,20,30,63], linked to pulmonary
exacerbations [1,63], and demonstratedtoproducequorum-sensing
signal molecules [63]. SMG-related Streptococcus were identified in
Patient 2-sample 2 and Patient 3-sample 2 (Figure S7). These
phylogenetically identified SMG members (their sequences clus-
tered with the SMG sequences of Streptococcus anginosus, S. intermedius,
and S. constellatus in figure S7, using Neighbor-joining approach)
were not numerically dominant compared to other clades, in
agreement with the clinically reported absence of pulmonary
exacerbation. Phylogenetic analysis of pyrosequences correspond-
ing to the genera Haemophilus and Malassezia did not provide any
new information compared to the pyrosequencing analysis using
BLASTN and MEGAN software.
Using the same phylogenetic method, we observed diversity
among genotypes of C. albicans, C. parapsilosis and A. fumigatus, with
the same genotypes shared between patients, and/or genotypes
that persisted over time within patients (Figures S5, S8, S9), in
agreement with published data [40,64]. Candida albicans and C.
parapsilosis represented typical dominant yeasts isolated from CF
sputa [2,4,5,40,65] for which we observed diversity similar to that
already reported (mainly a single predominant C. albicans
genotype) [40]. Regarding the aspergilli, samples were mainly
composed of A. fumigatus as shown in the phylogenetic analysis
(Figure S5), except for Patient 2-sample 1 in which the Aspergillus
genus showed a high diversity, including non-fumigatus Aspergillus
(Figure S2B, and sequences in dark green in Figure S5). Among A.
fumigatus pyrosequences of Patient 3, one genotype was predom-
inant in both samples of the patient, in agreement with previous
studies that have demonstrated the emergence of a single genotype
from a multiple-genotype population when chronic infection has
been established [64,66,67].
Several recent taxonomic studies have identified cryptic species
within key clinical morpho-species of both yeast and molds,
including the C. parapsilosis complex, the A. fumigatus species
complex and the S. apiospermum complex, which are particularly
involved in CF lung colonization [46,47,68–70]. Here, we were
able to differentiate C. metapsilosis genotypes from C. parapsilosis
genotypes (Figure S7), as well as A. lentulus from A. fumigatus (Figure
S5). This may have therapeutic implications given the different
antifungal susceptibility profiles of these species [40,45,71].
The relative amounts (expressed as percentage of reads in each
sample) of C. albicans or A. fumigatus were not statistically correlated
with any bacterial taxon, neither anaerobic bacteria, nor
Pseudomonas, nor Streptococcus. Nevertheless C. albicans was frequent-
ly associated with P. aeruginosa (80% of cases), which may be related
to its recently proposed core status [21] and the bidirectional
signalling pathway observed [for review60,72–75]. Patient 3-
sample 2 had a high number of A. fumigatus pyrosequences (23.6%)
and this was associated with a predominance of Streptococcus
(44.4%), which is a genus known to produce quorum-sensing
molecules and to induce interactions between microorganisms,
particularly among SMG members isolated from CF patients [63].
Regarding the temporal changes in the microbiota in each patient,
we observed similar patterns, namely a disappearance of or major
decrease in some bacterial genera recently described as members
of the ‘‘core’’ pulmonary microbiome [76] and known to be a part
of the oral bacterial community coupled with the emergence of
Table 4. Cont.
Sequences (reads)
a per patient and per sample
Identification Patient 1 Patient 2 Patient 3 Patient 4
Sample1 Sample 2 Sample1 Sample2 Sample1 Sample2 Sample1 Sample2
Agaricales 002000 0 0
Physalacriaceae 001000 0 0
S t r o b i l u r u s 006000 0 0
Tremellomycetes 0 0 91 0 0 0 0 0
Dioszegia 0 0 129 0 0 0 0 0
Sporobolomyces 007000 0 0
Microbotryomycetes 001200 4 0
Sporidiobolales 0 0 11 5 0 0 52 0
Sporobolomyces 000000 8 0
Ustilaginomycotina 9081 4 01 0 0 3
Entylomataceae 002000 0 0
Entyloma 0 0 73 0 0 0 0 0
Malassezia 473 0 201 302 0 338 0 75
Microstromatales 000000 0 9
Quambalaria 000000 0 1 4
aOnce a read was assigned to the highest taxonomical level according to the criteria defined in material and method section, it was not added up in the next taxonomic
level.
doi:10.1371/journal.pone.0036313.t004
Lung Microbiote in Cystic Fibrosis
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e36313more pathogenic bacteria (loss of Prevotella in Patients 1, 2, 3, and
4, Gemella in Patients 2, 3, and 4, Veillonella in Patient 3 associated
with the emergence of P. aeruginosa in Patients 1 and 3, and of H.
influenzae in Patient 2). Similarly, C. albicans, A. fumigatus or A.
lentulus were detected in the second samples of Patient 1 and
Patients 2, 3, and 4, respectively, while fungal species or genera
known to be poorly pathogenic disappeared.
On the whole, our study highlights the correlation between richness
and diversity of fungal and bacterial microbiota (Figure 2). We
therefore suggest that ‘‘colonization resistance’’ occurs in CF lower
airways, similar to what has been proposed to explain the exclusion of
pathogenic species from the gut and the mouth by the presence of a
specific microbiota [59,77–79]. This phenomenon may be due to a
range of factors and microbe-microbe interactions, including the
presence of ‘‘synergens’’ described as enhancing the pathogenicity of
the whole microbiota [78,79], that will be discussed below.
Discussion
Given the recent evidence that fungi may be of clinical relevance
in the decline of CF lung function, associated with co-colonization
of fungi and bacteria [5,22,49,80], we coupled fungal analysis to the
characterizationofbacterial florain sputum samples from CFadults
using the pyrosequencing technique. We acknowledge that the
present CF cohort is small but comparable to sample size recently
published (from 4 to 14 sputum samples [17,23,76]), lacks a specific
control group — which is difficult to choose [7], e.g. there can be
extensive overlap of bacterial membership between the pulmonary
microbiome of healthy subjects and patients with or without COPD
[76] —, and probably is not completely representative of the full
spectrum of CF pulmonary pathology. However, this pyrosequenc-
ing-based study of fungal and bacterial communities in the human
airwayconfirmed the recently reported bacterial diversity (including
anaerobes) in CF patients [8,17,20,23,24] as well as in COPD
patients using BAL [76], and revealed complex fungal biota in
sputum samples, with a majority of the fungal species or genera
obtained by pyrosequencing not identified in cultures, most of them
known to be pathogens. Using phylogenetic tools, we also found
infraspecific diversity in C. albicans, C. parapsilosis and A. fumigatus
similar to previous published data [40,42,64,66,67]. In parallel,
cryptic and new unculturable (or difficult to grow in vitro) species
have also been identified, most of them described as human
pathogens. In agreement with a recent oligonucleotide array
analysis [9], we showed that fungal microbiota colonizing the lower
airways of CF patients is more diverse and complex than previously
estimated with culture methods. Therefore, culture methods are
probably inadequate for assessing CF respiratory fungal microbiota,
although culture methods can be improved with increased
standardization [3,81] and are still required to determine drug
susceptibility. Moreover, we have evidence that poor clinical status
is associated with lower taxon diversity and richness in fungal and
bacterial communities (decrease in S-K scores, BMI, FVC, and
FEV1 values significantly associated with low Chao1 indices).
Our findings add support to (i) the pathogenicity of species
derived from the oral cavity and usually considered as clinically
insignificant such as anaerobes and SMG members, even if their
role in infection and inflammation needs to be further elucidated
[1,8,17,20,23,29,31,63,79], and (ii) the complex interaction
between typical pathogens and microbiota, such as the association
between P. aeruginosa and anaerobes [20,30,58,59]. Since C. albicans
and C. parapsilosis can also be part of oral flora, these yeasts can
migrate from the oral environment, colonize and persist within the
lower airways of CF patients [40], as proposed for bacteria [23].
Although the implication of C. albicans in the decline of CF lung
function has been recently suggested [49], the clinical relevance of
yeasts is still matter of debate, and remains to be confirmed. Given
the airborne transmission of molds such as A. fumigatus,
opportunistic molds represent the most common agents of fungal
colonization and/or infection of the CF airways. Among them, A.
fumigatus has been reported more and more frequently since the
2000s [3–5,9], and is associated with clinical significance in CF
[80] and modification in the population of genotypes during
chronic colonization [64,66,67]. Fungal colonization (especially
repeated or chronic colonization) may have a substantial impact
on the development of CF pulmonary disease [43,49,80], but
more studies are required to determine this fungal risk, especially
in light of the concomitant bacterial biota.
Given the relationship between decreased microbiota diversity
and poor clinical status, we hypothesize that the composition of
the microbial community in CF airways is the result of dynamics
that take into account the different microorganisms present as an
Figure 2. Relation between species richness and clinical status
(A) or lung function (B). Total richness of prokaryotic and fungal
communities from each patient-sample was expressed using the Chao1
richness estimator; each spot size is proportional to the corresponding
Chao1 value. The clinical status is expressed as S-K score and BMI in
Figure 2A, while lung function is expressed as FEV1 and FVC values in
Figure 2B. Given to the absence of S-K score value from Patient 2-
sample 2 (Table 1), this spot is missing in Figure 2A. Bacterial and fungal
Chao1 values corresponding to Patient 1, Patient 2, Patient 3, and
Patient 4 are represented in blue-, green-, red- and yellow-edged spots,
respectively. Dark and light colour intensity is corresponding to the first
and second sampling dates of each patient, respectively. Dark grey and
light grey are corresponding to fungal and bacterial Chao1 richness
values, respectively.
doi:10.1371/journal.pone.0036313.g002
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inter-species level. This is somewhat similar to the constitution of
oral microbial consortia for which the potential for infection or co-
infection is realized when potential pathogens find suitable
community partners and local conditions (host response, adhesion
receptors, biofilm formation) [59]. It is well known that the
heterogeneity of mucus composition in CF provides suitable
conditions for chronic infection by a wide range of microorgan-
isms. In particular, recent data indicate that reduced oxygen
tension in CF lung promotes the growth of P. aeruginosa [82,83], as
well as other anaerobic bacteria [1,30]. Candida albicans can also
grow under anaerobic conditions, showing mating type modifica-
tions that may promote yeast development [84,85].
In addition to local physical conditions, both bacteria and fungi
possess the ability to form biofilm consortia [63,82,83,86–88]. In
this context, direct and indirect microbe-microbe interactions have
been well documented, particularly those involving the major
prokaryotic CF pathogen: P. aeruginosa (for review, see [89]).
Pseudomonas aeruginosa can produce substances that modulate growth
of other microorganisms, in particular fungi. Pseudomonas aeruginosa
and C. albicans can coexist, or have an antagonistic influence as
recently proposed between P. aeruginosa and A. fumigatus
[60,72,90,91]. Moreover, C albicans produces farnesol, which in
addition to its quorum-sensing function regulating yeast morpho-
genesis and its ability to modify P. aeruginosa growth, also reduces
competition from other fungi such as A. fumigatus [92]. Because a
large proportion of bacteria have been shown to synergistically
affect CF disease outcome by modifying the expression of virulence
genes [79], it may not be surprising to find evidence of such
synergistic interactions within the fungus community.
Thus, analyzing microbial diversity in polymicrobial samples such
as CF sputa is the type of study for which metagenomic methods have
been recently proposed [16,18,21,78]. Our results, along with others
[16–18,24,76], demonstrate the utility of high-throughput sequencing
in identifying microorganisms to investigate the microbiome
associated with chronic pulmonary diseases, such as CF or COPD.
These results now need to be confirmed by further pyrosequencing
studies, especially in large multicenter studies that will lead to a better
understanding of the dynamics of such CF microbiota.
In the near future, microbiota complexity should be taken into
account to analyze host-microbe interactions, which are bi-
directional and probably not limited to the direct contact lung
area (as proposed in ref. [61]). The analysis of CF pulmonary
disease and its management should be reassessed in light of these
interactions. This concept of CF lung microbiota has emerged
recently from the scientific community working on the microbi-
ology of the CF respiratory tract [61,78], and entails coupling
environmental microbiological approaches with community ecol-
ogy analyses (i.e. analyzing species richness and relative species
abundance in terms of either spatial or temporal distribution and
dividing species into core and satellite groups, at an ecologically
relevant spatial scale) [23,31,61,76]. Furthermore, these molecular
results should be combined with biological models, such as biofilm
models or in vivo planktonic cultures as recently proposed, in
order to elucidate the possible interaction between bacteria and
fungi detected here [59,63,82,83,86–93].
Few culture-independent strategies have been developed to
evaluate bacterial [1,8,16,17,20,23,24,29,31], fungal [9], and viral
[18] diversities in sputum samples from CF patients. Thus, new
high-throughput sequencing approaches offer more exhaustive
coverage of the sequences present in PCR products, in particular
when the new generations of automatic sequencers, such as the GS
FLX Titanium System, are used. Compared to terminal restriction
fragment length polymorphism (T-RFLP) analysis, high-through-
put sequencing methods more accurately identify pathogens,
because they are based on sequences instead of amplicon sizes that
can be shared between two or more species. For example, S.
sanguinis, S. parasanguinis and S. salivarius all generate a 576 bp T-
RFLP fragment [1].
Nevertheless, these molecular strategies can have some
confounding factors. One important drawback due to the basic
PCR approach is the incapacity to reflect the viability of the
microorganisms detected by DNA amplification, unless samples
are pre-treated (with, for example, propidium monoazide, [61]).
Furthermore, DNA extraction from clinical samples is the first
crucial step in ensuring faithful molecular detection. Non-
homogenous lysis of bacterial and fungal cells, which are known
to require strong lysis in order to extract DNA, may introduce
biases as in any method based on DNA amplification [94,95]. In
addition to DNA extraction efficiency that can vary between
microorganisms, the choice of the PCR protocol, from primer
design to the number of PCR cycles, can affect the results. In
contrast to specific PCR targeting a specific pathogen, high-
throughput methods as well as cloning/sequencing techniques, are
based on amplification with primers targeting conservative regions
of microorganism DNA. These techniques can thus identify any
microorganism that is reasonably abundant within the sample
without the need for prior prediction of which species may be
present. This universal-primer approach leads to the preferential
amplification of the most prevalent flora. This bias may explain
the negative pyrosequencing results for P. jirovecii, which may be
present in small numbers since only nested-PCR was positive (not
detected upon direct examination). The clonal Sanger-sequencing
approach would be more suitable than pyrosequencing methods
for identifying microorganisms in relatively low abundance [8].
Improvements in amplicon length with the next generation of
sequencers will determine the capacity to analyze amplicon
diversity and to assign amplicons to species instead of genera.
Additionally, the prominent advantage of pyrosequencing is its
automation, which leads to increased standardization, from DNA
extraction to sequencing analysis, allowing multicenter studies to
be carried out at without compromising reproducibility.
Conclusion
The aim of microbiological diagnosis from CF patients is to
provide data with which clinicians can make rational and effective
therapeutic decisions. Given the currently acknowledged polymi-
crobial nature of CF sputa [1,8,9,17,29,31], better knowledge of
sputum microbiota would represent a major advance in our
understanding of the disease. In light of this concept of CF lung
microbiota [61,78,96], high-throughput sequencing, due to its
potential for massive direct sequencing after a single run of DNA
amplification and automation, appears to be the most promising
approach. The present study should stimulate a debate over the
best way to set up new studies with the aim of combing (i) new
technology (deep-sequencing), (ii) ecological tools (to analyze
dynamics, diversity and relative species abundance, as species
distribution is ecologically important in terms of community
interactions [31,78]), and (iii) clinically relevant information (e.g.
pulmonary exacerbation in which SMG bacteria have been
implicated when chronic colonization by P. aeruginosa develops a
loss of virulence [1]) as well as the impact of therapeutics (long-
term antibiotics cause a decline in bacterial diversity and
inadvertently allow P. aeruginosa to flourish [58]; little is known
about the impact of azole on fungal biota in CF).
Clearly, further metagenomic research, for which a scientific
framework is needed as are well-designed translational studies, is
now warranted to enhance knowledge of the process that drives the
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bacterial plus fungal microbiota present in CF lower airways has the
potential to dramatically improve survival in CF patients. Moreover,
it will pave the way for developing personalized drug therapy
strategies based on the manipulation of complex microflora (i.e.
controlling growth of less desirable microorganisms or controlling
biofilm-associated infections as recently proposed [59,89]).
Materials and Methods
Sample collection and DNA extraction
Patients were eligible if they could be classified as clinically
stable (i.e., being followed-up during their annual check-up
without exacerbation status). All volunteers with CF were required
to have a well-documented diagnosis, with either the two
mutations identified in the CFTR gene or an abnormally high
sweat chloride test (Table 1). The four CF individuals selected for
the study consisted of two males and two females, with an age
range of 19 to 39 years. All clinical, therapeutic, radiological, and
biological data were collected by clinical staff at the time of the
visit (Tables 1 and 2). Human sputum samples (two samples
collected for each patient at two visits) were collected by
expectoration into a sterile cup after a water rinse to prevent
excessive salivary contamination, [17,23,31]. Sputa were homog-
enized for 30 min at 37uC with Digest-EURH (Eurobio, France) in
1:1 (v:v) ratio (final volume of approximately 10 ml), and
mycological cultures were performed after direct examination, as
previously described [4]. Briefly, 20 ml aliquots of the digested
sample were inoculated onto three growth media: CandiSe-
lectTM4 (Bio-Rad; incubation at 37uC for 3 weeks), Sabouraud
glucose peptone agar with 0.5 g/L amikacin (incubation at 25uC
for 3 weeks), and 1:2 diluted Sabouraud glucose agar with 0.5 g/L
amikacin (incubation at 25uC for 3 weeks). All sputa were
inoculated in parallel onto five agar plates including chocolate
Poly ViteX agar, Columbia colistin-nalidixic acid agar, Bromo
Cresol Purple agar, blood agar (all purchased from bioMe ´rieux,
France) and incubated at 37uC for 48 h) and Cepacia agar
(purchased from AES Laboratory, France), and incubated at 30uC
for 5 days). Colonies growing on these media were identified using
conventional methods or spectrometry. Then, 200 mL of each
digested sample were frozen at 220uC until use. Samples were
first ground in liquid nitrogen with a mortar and pestle. DNA was
then extracted using the High Pure PCR Template Preparation kit
(Roche Applied Science, Germany) according to manufacturer’s
protocol, except for the proteinase K digestion step, which was
performed for 1 h at 70uC rather than 10 min. Total DNA
concentrations ranged from 50 to 75 ng/mL, using NanoDropH
ND-1000 spectrophotometer. A nested PCR targeting Pneumocystis
jirovecii, a difficult-to-culture micromycete, and a real-time PCR
targeting Aspergillus fumigatus, were retrospectively done as
described previously [26,27]. No significant PCR inhibitions were
observed when DNA samples were diluted in 1/10.
Ethics Statement
Sputa from four CF patients who volunteered for the study were
collected at the Lille Adult CF center, in accordancewiththe ethical
guidelines of Lille University Hospital. This study was part of the
‘‘MucoFong’’ protocol and was approved by the Institutional
Human Care and Use Committee of the Lille University Hospital
(Comite ´ de Protection des Personnes Nord Ouest IV - reference
Number CPP 06/84; assurance number: SHAM 127795). Written
informed consents were provided by study participants.
Pyrosequencing analysis
Two sets of primers were used to amplify the 16S rDNA and
ITS2 loci from prokaryotes and fungi, respectively. The first set of
primers, 3271-16S-F (TACGGRAGGCAGCAG) and 3271-16S-R
(GGACTACCAGGGTATCTAAT), was designed to amplify a
465 bp region containing the complete V3 domain of all
prokaryotic 16S rDNA genes [97]. The second set, composed of
primers 3271-ITS2F (CARCAAYGGATCTCTTGG) and 3271-
ITS2R (GATATGCTTAAGTTCAGCGGGT) was designed to
amplify a 340–360 bp fragment of the ITS2 region from all major
phylaoffungi,accordingtothe use forreconstructingphylogeniesat
a highertaxonomical levelofthis region[98].A 10 bptagspecificto
each of the eight samples, a 4 bp TCAG key, and a 21 bp adapter
for the GS FLX system, were added to the sequences of both
primers sets. PCRs were carried out using standard conditions for
Taq DNA polymerase with 10 ng of DNA as template. After the
denaturation step at 95uC for 5 min, 35 cycles of amplification were
performed with a GeneAmp PCR System cycler (Applied
Biosystems) as follows: 30 s at 95uC, 30 s at 50uCa n d1m i na t
72uC. Each DNA sample was analyzed in duplicate. The
Genoscreen company (Pasteur Institute of Lille, France) carried
out the pyrosequencing. The library and the 454 GS FLXTitanium
(Roche) pyrosequencing runs were prepared according to manu-
facturer’s recommendations. We obtained 326,277 and 133,317
sequences with the first (16S prokaryotes) and second (ITS2 fungi)
set of primers, respectively. The sequences or reads were classified
according to the presence of the tag corresponding to each of the
eight samples of interest. Primers, tag and key fragments were not
included in sequence analysis.
For identification, the 16S rDNA gene sequences were
compared to the Silva SSU rRNA database (http://www.arb-
silva.de/) release 102 (updated on February 15, 2010) comprising
1,246,462 SSU rRNA sequences using BLASTN software [99].
For ITS2 sequence identification, we constructed a fungal ITS2
database, based on the following steps: (i) a search through the
complete nucleotide database of GenBank for potential ITS2
sequences, (ii) selection of ITS2 sequences that included the
sequences of the primers designed in the present study, and (iii)
inclusion of human genome sequences that were 500 bp long with
at least one of the two primers to filter sequences belonging to host
human cells (indicated as ‘‘Homo sapiens’’ in the final taxonomic
assignment of the pyrosequencing ITS2 reads). This ITS2
database, named ITS2dbScreen, is available on request via the
web site of the Genoscreen company (www.genoscreen.fr).
BLAST results (with a 10
25 E-value threshold) were visualized
using the metagenomic software MEGAN [100]. Based on NCBI
taxonomy, this software explores the taxonomic content of the
samples with the option ‘‘import BLASTN’’. The program uses
several thresholds to generate sequence-taxon matches. The ‘‘min-
score’’ filter, corresponding to a bit score cutoff value, was set at 35
for 16S rDNA amplicons as previously described [19], and at 200
for ITS2 amplicons to obtain an alignment with a minimum of
100 nucleotides. The ‘‘top-percent’’ filter used to select hits whose
scores lay within a given percentage of the highest bit score, was
set at 10 and at 5 for 16S rDNA and the ITS2 loci, respectively.
The ‘‘min-support core’’ filter, used to set a threshold for the
minimum number of sequences that must be assigned to a taxon,
was set to 5. These stringent parameters should result in a
‘‘conservative’’ assignment of many sequences to internal branches
(i.e. with less precision) of the taxonomic tree. Distribution of the
sequences was schematically represented by Neighbor-Joining (NJ)
tree diagrams (Figures S1, S2, S3, S4).
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The quality of the sampling effort was assessed through the
calculation of rarefaction curves, i.e. the number of operational
taxonomic units (OTUs) with respect to the number of reads
[101]. The prokaryote 16S rDNA and fungus ITS2 pyrosequences
were sorted by decreasing length and clustered with 97% similarity
using Uclust (http://www.drive5.com/usearch/) [102]. Rarefac-
tion curves were calculated according to Uclust results using a perl
script. The total richness of a community from a patient-sample
was estimated using the Chao1 richness estimator [103]. This non-
parametric estimator allows cross-sample comparison of species
diversity. The Chao1 index was calculated from Uclust results
using the formula: Chao1=n+(n1*(n121))/(2*(n2+1)), where n is
total number of OTUs, n1, the number of OTUs composed of one
read, and n2, the number of OTUs composed of two reads. These
diversity indices and richness estimators were then used to
compare the relative complexities of communities and to estimate
the completeness of sampling.
Phylogenetic analysis
The phylogenetic trees inferred from 16S rDNA and ITS2
pyrosequences were used to compare biodiversity of specific taxa
or within genera between samples for the same patient and/or
between patients. The bacterial 16S rDNA sequences correspond-
ing to the genera Streptococcus, Haemophilus and Pseudomonas, and the
fungal ITS2 rDNA reads corresponding to those of Aspergillus,
Candida and Malassezia were extracted from the pyrosequencing
database using MEGAN, individually sorted by size, and clustered
by homology (with a 97% identity threshold) using Uclust [102].
The longest read (.400 bp) from each cluster was selected as the
representative sequence and submitted to a BLAST search [99] on
the non-redundant nucleotide database (NCBI) to determine an
approximate phylogenetic affiliation. The representative sequenc-
es and reference sequences were aligned using Muscle [102] as
implemented in the SeaView4 program [104]. The resulting
alignments were manually curated with the BioEdit software
(http://www.mbio.ncsu.edu/bioedit/bioedit.html), and phyloge-
netic trees were constructed using both the NJ method from the
SeaView4 package [104] and the Bayesian method implemented
in MrBayes3 software (http://mrbayes.csit.fsu.edu/index.php)
[105]. Since topologies of the phylogenetic trees generated by
the two methods were similar, only the NJ trees are shown. The
reliability of internal branches was assessed using the bootstrap
method implemented in SeaView4 with 1000 replicates; only
probabilities of more than 50% are shown at the tree nodes.
Phylogenetic trees were edited using Dendroscope [106].
The pyrosequences were deposited in GenBank-SRA under the
accession number SRA049426.2.
Statistical analysis
Numerical variables were described as medians and interquar-
tile ranges (Q1, Q3). To study the relationship between clinical
data, taxon richness, and community composition of sputum
samples, Spearman’s correlation coefficient were calculated. P-
values of less than 0.05 were considered as significant. All statistical
analyses were performed using SAS software (SAS Institute, Cary,
NC, USA; version 9.2).
Supporting Information
Figure S1 Taxonomic assignment of the 16S rDNA (A)
and ITS2 (B) reads obtained from Patient 1.
(TIF)
Figure S2 Taxonomic assignment of the 16S rDNA (a)
and ITS2 (b) reads obtained from Patient 2.
(TIF)
Figure S3 Taxonomic assignment of the 16S rDNA (a)
and ITS2 (b) reads obtained from Patient 3.
(TIF)
Figure S4 Taxonomic assignment of the 16S rDNA (a)
and ITS2 (b) reads obtained from Patient 4. Footnotes for
figures S1 to S4. Reads obtained from sputum samples of Patients
1–4 were analyzed using the software MEGAN, after BLASTN
search against databases (see Material and Methods section). The
MEGAN software plots on schematic trees represent the number
of pyrosequence reads matching a particular taxonomical group.
The tree displays all taxonomic groups identified from the
assignment of reads obtained either with prokaryotic primers
(Figures S1A–S4A), or fungus-designed primers (Figures S1B–
S4B).
(TIF)
Figure S5 NJ-phylogenetic tree of ITS2 sequences from
the genus Aspergillus.
(TIF)
Figure S6 NJ-phylogenetic tree of 16S rRNA sequences
from the genus Pseudomonas.
(TIF)
Figure S7 NJ-phylogenetic tree of 16S rRNA sequences
from the genus Streptococcus.
(TIF)
Figure S8 NJ-phylogenetic tree of ITS2 sequences from
Candida albicans.
(TIF)
Figure S9 NJ-phylogenetic tree of ITS2 sequences from
the Candida parapsilosis complex. Footnotes for figures S5
to S9. Neighbor-joining trees of the ITS2 or 16SrRNA sequences
from the genus Aspergillus (Figure S5), Pseudomonas (Figure S6), and
Streptococcus (Figure S7), and the species C. albicans (Figure S8) and
the C. parapsilosis complex (Figure S9). The representative
sequences corresponding to Patient 1 in blue, Patient 2 in green,
Patient 3 in red and Patient 4 in yellow, while dark and light
colour intensity were corresponding to the first and second
sampling dates, respectively. Numbers in brackets indicate the
number of reads composing each cluster. Clusters composed of
reads that are at least 50% greater than the number of reads
composing the most dominant cluster are in bold. Bootstrap values
(threshold .50) are indicated at the nodes.
(TIF)
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